

## AlzeCure Pharma AB publishes prospectus and invites to investor presentations

AlzeCure Pharma AB (publ) ("AlzeCure" or the "Company"), a pharmaceutical company that develops a broad portfolio of small molecule drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the Swedish Financial Supervisory Authority (the "SFSA", sw. Finansinspektionen) has approved the prospectus that AlzeCure has prepared due to the upcoming rights issue. The prospectus is available at AlzeCure's website ([www.alzecurepharma.se](http://www.alzecurepharma.se)) and Erik Penser Bank's website ([www.penser.se](http://www.penser.se)). Because of the rights issue, AlzeCure invites to four investor meetings during March.

### Prospectus

The prospectus that AlzeCure has prepared due to the upcoming rights issue has today been approved and registered by the SFSA. The prospectus, containing complete terms and instructions, and application forms can be obtained from AlzeCure and Erik Penser Bank and is available at AlzeCure's website ([www.alzecurepharma.se](http://www.alzecurepharma.se)) and Erik Penser Bank's website ([www.penser.se](http://www.penser.se)). The prospectus will also be available at the SFSA's website ([www.fi.se](http://www.fi.se)).

### Invitation to investor meetings

AlzeCure's CEO, Martin Jönsson, will present the Company's operations and future plans on the following occasions:

- March 9, 2022 at 18:00 at Erik Penser Bank, Apelbergsgatan 27, Stockholm
- March 15, 2022 at 16:30 at Aktiespararna Stockholm with Aktiespararna, Birger Jarlsgatan 61A, Stockholm
- March 16 at 14:45 at BioStock Investor Meeting, virtual meeting (see link below)
- March 21, 2022 at 12:00 at Erik Penser Bank, Apelbergsgatan 27, Stockholm.

Registration to attend must be submitted to Aktiespararna, through [www.aktiespararna.se](http://www.aktiespararna.se) and to Erik Penser Bank, through <http://enews.penser.se/public/event/RegistrationForm/4343584774444A59457040>. Please note that the number of seats are limited.

The presentation at Erik Penser Bank on March 9, 2022, will be available on Erik Penser Bank's youtube channel.

The presentation at Aktiespararna on March 15, 2022, will be available on [www.aktiespararna.se/tv/live](http://www.aktiespararna.se/tv/live).

The presentation at BioStock on March 16, 2022, will be available on <https://youtu.be/tv-ZDUn3zzl>.

The presentations will be held in Swedish. The presentations will also be available afterwards on AlzeCure's website <https://www.alzecurepharma.se/en/presentations-and-interviews/>.

### Summary of the rights issue

- One (1) existing share in AlzeCure held on the record date March 4, 2022, entitles to one (1) subscription right. Five (5) subscription rights entitle to subscribe for two (2) newly issued shares.
- The subscription price amounts to SEK 4.00 per share. Payment must be made in cash.

- Through the Rights Issue, AlzeCure can receive a maximum of approximately SEK 60.4 million before issue costs.
- To enable additional capital injection, the Board may exercise an over-allotment option of up to SEK 12.0 million (the "Over-allotment Option"). If the Over-allotment Option is exercised in its entirety, the maximum capital injection amounts to approximately SEK 72.4 million. The exercise of the Over-allotment Option is contingent on resolution by the Board of Directors to issue new shares with the support of the existing authorization to issue new shares.
- The subscription period runs during March 8 - 22, 2022.
- Trading in subscription rights will take place on the Nasdaq First North Premier Growth Market during the period March 8 - 17, 2022.
- The Rights Issue implies that the Company's share capital increases by a maximum of SEK 377,657.15, corresponding to a maximum of 15,106,286 shares, implying a maximum dilution of 28.6 percent.
- The Rights Issue is secured with subscription commitments and guarantee commitments to a total of SEK 48.5 million. The subscription commitments amount to approximately SEK 13.9 million, corresponding to approximately 23.0 percent of the Rights Issue and the guarantee commitments amount to approximately SEK 34.6 million, corresponding to approximately 57.3 percent of the Rights Issue. Subscription and guarantee commitments from management and board members amount to a total of SEK 2.1 million.

## Advisors

In connection with the Rights Issue, AlzeCure has hired Erik Penser Bank AB and Synch Advokat AB as financial and legal advisers.

## Important information

*The information in this press release does not contain nor constitute an offer to acquire, subscribe for or in any other way trade with shares, warrants or other securities in AlzeCure. No measures have been taken and no measures will be taken in order to allow for an offer to the public in any other jurisdictions than Sweden. Offer to for the relevant persons to subscribe for shares in AlzeCure is only made through the prospectus which AlzeCure now has published.*

*The information in this press release may not be made public, be published or distributed, directly or indirectly, within or to USA, Australia, Hongkong, Japan, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require other actions than what is stipulated under Swedish law. Any actions not in compliance with these instructions may constitute a violation against applicable securities regulation. No shares or other securities in AlzeCure have been registered, and no shares or other securities will be registered, under United States Securities Act of 1933 ("Securities Act") as in force from time to time or under the securities laws in any state or other jurisdiction in the US and may not be offered, sold or in any other way transferred, directly or indirectly, in or to the US, except for pursuant to an applicable exemption from, or in a transaction not subject to, the registration rules in the Securities Act and in compliance with the securities regulations in the relevant state or other jurisdiction in the US. This communication is distributed and aimed for only persons in Great Britain who are (i) professional investors under Article 19(5) in UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("Order") as in force from time to time or (ii) subjects with a high net wealth and other persons to whom this message can be legally addressed, who are subject to Article 49(2)(a)-(d) in the Order (all those persons referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment action referred to in this communication is only possible for Relevant Persons and will only be closed with Relevant Persons. Persons who distribute this communication must themselves make certain that such distribution is allowed.*

## Forward-looking statements

*This press release contains forward-looking statements regarding the Company's intentions, assessments, or expectations in respect of the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market within which the Company operates. Forward-looking statements are statements which do not refer to historical facts and which typically contain words such as "considers", "expects", "predicts", "intends to", "estimates", "will", "can", "presumes", "should", "may" and, in each case, negations thereof or other similar expressions. The forward-looking statements in this press release are based on different assumptions which, in several cases, are based on additional assumptions. Even if the Company considers the assumptions which are reflected in these forward-looking statements to be true, it cannot be guaranteed that they will in fact occur or that they are correct. Given that these assumptions are based on assumptions or estimates and that they are subject to risks and uncertainties, the actual result may, for many reasons, substantially deviate from what is stated in the forward-looking statements.*

*Such risks, uncertainties, eventualities, and other significant factors may lead to the actual events deviating substantially from the expectations that have been explicitly or implicitly provided for under this press release through the forward-looking statements. The Company does not guarantee that the assumptions which the forward-looking statements in this press release are based on are correct, and a reader of this press release should not unduly rely on the forward-looking statements contained herein. The information, opinions, and forward-looking statements which are either explicitly or implicitly presented herein, are only provided as of the day of this press release and may be subject to change. Neither the Company nor anyone else undertakes to oversee, update, confirm or provide public notification in respect of any change of any forward-looking statement for the purpose of reflecting the actual events or circumstances which occurs in respect of the content of this press release, unless required by law or Nasdaq First North Growth Market's rules for issuers.*

## For more information, please contact

---

Martin Jönsson, CEO  
Tel: +46 707 86 94 43  
[martin.jonsson@alzecurepharma.com](mailto:martin.jonsson@alzecurepharma.com)

## About AlzeCure Pharma AB (publ)

---

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 [info@fnca.se](mailto:info@fnca.se), is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se)

## Attachments

---

AlzeCure Pharma AB publishes prospectus and invites to investor presentations